Skip to main content

Amgen Stock Forecast, Price & News

$252.60
+1.22 (+0.49 %)
(As of 05/17/2021 11:40 AM ET)
Add
Compare
Today's Range
$250.94
$253.69
50-Day Range
$234.71
$259.14
52-Week Range
$210.28
$276.69
Volume41,185 shs
Average Volume2.73 million shs
Market Capitalization$145.13 billion
P/E Ratio20.37
Dividend Yield2.80%
Beta0.76
30 days | 90 days | 365 days | Advanced Chart
Receive AMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.


Amgen logo

About Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AMGN
CUSIP03116210
Phone(805) 447-1000
Employees24,300
Year Founded1980

Sales & Book Value

Annual Sales$23.36 billion
Cash Flow$19.46 per share
Book Value$16.28 per share

Profitability

Net Income$7.84 billion

Debt

Price-To-Earnings

Miscellaneous

Market Cap$145.13 billion
Next Earnings Date7/27/2021 (Estimated)
OptionableOptionable

Social Links


MarketRank

Overall MarketRank

2.26 out of 5 stars

Medical Sector

20th out of 2,032 stocks

Biological Products, Except Diagnostic Industry

4th out of 176 stocks

Analyst Opinion: 2.2Community Rank: 3.0Dividend Strength: 2.5Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Amgen (NASDAQ:AMGN) Frequently Asked Questions

Is Amgen a buy right now?

25 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 2 sell ratings, 9 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Amgen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
View analyst ratings for Amgen
or view top-rated stocks.

What stocks does MarketBeat like better than Amgen?

Wall Street analysts have given Amgen a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Amgen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Amgen's next earnings date?

Amgen is scheduled to release its next quarterly earnings announcement on Tuesday, July 27th 2021.
View our earnings forecast for Amgen
.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) posted its earnings results on Monday, April, 26th. The medical research company reported $3.70 EPS for the quarter, missing the Zacks' consensus estimate of $4.05 by $0.35. The medical research company had revenue of $5.90 billion for the quarter, compared to the consensus estimate of $6.30 billion. Amgen had a trailing twelve-month return on equity of 95.55% and a net margin of 29.42%. The business's quarterly revenue was down 4.2% on a year-over-year basis. During the same period last year, the business earned $4.17 earnings per share.
View Amgen's earnings history
.

How has Amgen's stock price been impacted by Coronavirus?

Amgen's stock was trading at $198.65 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AMGN shares have increased by 27.3% and is now trading at $252.87.
View which stocks have been most impacted by COVID-19
.

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen announced a quarterly dividend on Wednesday, March 3rd. Shareholders of record on Monday, May 17th will be given a dividend of $1.76 per share on Tuesday, June 8th. This represents a $7.04 annualized dividend and a yield of 2.78%. The ex-dividend date of this dividend is Friday, May 14th.
View Amgen's dividend history
.

Is Amgen a good dividend stock?

Amgen pays an annual dividend of $7.04 per share and currently has a dividend yield of 2.80%. Amgen does not yet have a strock track record of dividend growth. The dividend payout ratio of Amgen is 47.50%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Amgen will have a dividend payout ratio of 41.41% next year. This indicates that Amgen will be able to sustain or increase its dividend.
View Amgen's dividend history.

What guidance has Amgen issued on next quarter's earnings?

Amgen issued an update on its FY 2021 earnings guidance on Tuesday, May, 4th. The company provided earnings per share guidance of 16.000-17.000 for the period, compared to the Thomson Reuters consensus EPS estimate of $16.800. The company issued revenue guidance of $25.80 billion-$26.60 billion, compared to the consensus revenue estimate of $26.41 billion.

What price target have analysts set for AMGN?

25 Wall Street analysts have issued 1 year target prices for Amgen's shares. Their forecasts range from $200.00 to $300.00. On average, they anticipate Amgen's share price to reach $255.86 in the next year. This suggests a possible upside of 1.2% from the stock's current price.
View analysts' price targets for Amgen
or view top-rated stocks among Wall Street analysts.

Who are Amgen's key executives?

Amgen's management team includes the following people:
  • Robert A. Bradway, Chairman, President & Chief Executive Officer (LinkedIn Profile)
  • Esteban Santos, Executive Vice President-Operations
  • Peter H. Griffith, Chief Financial Officer & Executive Vice President (LinkedIn Profile)
  • Mike Zahigian, Chief Information Officer & Senior Vice President (LinkedIn Profile)
  • David M. Reese, Executive Vice President-Research & Development

What is Robert A. Bradway's approval rating as Amgen's CEO?

806 employees have rated Amgen CEO Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among Amgen's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Amgen's key competitors?

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), The Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and The Home Depot (HD).

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Who are Amgen's major shareholders?

Amgen's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.49%), Primecap Management Co. CA (2.90%), Geode Capital Management LLC (1.68%), Northern Trust Corp (1.35%), Bank of New York Mellon Corp (1.11%) and Clearbridge Investments LLC (1.01%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, Nancy A Grygiel, R Sanders Williams and Ronald D Sugar.
View institutional ownership trends for Amgen
.

Which major investors are selling Amgen stock?

AMGN stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Primecap Management Co. CA, DekaBank Deutsche Girozentrale, Fiera Capital Corp, APG Asset Management N.V., Northern Trust Corp, Renaissance Technologies LLC, and Assetmark Inc.. Company insiders that have sold Amgen company stock in the last year include Jonathan P Graham, Nancy A Grygiel, R Sanders Williams, and Ronald D Sugar.
View insider buying and selling activity for Amgen
or view top insider-selling stocks.

Which major investors are buying Amgen stock?

AMGN stock was purchased by a variety of institutional investors in the last quarter, including FIL Ltd, Franklin Resources Inc., BlackRock Inc., Geode Capital Management LLC, Nordea Investment Management AB, Wilkinson Global Asset Management LLC, Cohen Investment Advisors LLC, and Clarus Group Inc..
View insider buying and selling activity for Amgen
or or view top insider-buying stocks.

How do I buy shares of Amgen?

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $252.87.

How much money does Amgen make?

Amgen has a market capitalization of $145.29 billion and generates $23.36 billion in revenue each year. The medical research company earns $7.84 billion in net income (profit) each year or $14.82 on an earnings per share basis.

How many employees does Amgen have?

Amgen employs 24,300 workers across the globe.

Does Amgen have any subsidiaries?

The following companies are subsidiares of Amgen: ATL Holdings II Limited, ATL Holdings Limited, Abgenix, Alantos Pharmaceuticals, Amgen (Europe) GmbH, Amgen Canada Inc., Amgen Fremont Inc., Amgen Global Finance B.V., Amgen GmbH Germany, Amgen Holding No. 1 Limited, Amgen K-A Inc., Amgen Manufacturing Limited, Amgen Rockville Inc., Amgen S.A.S., Amgen SF LLC, Amgen Technology, Amgen Technology (Ireland) Unlimited Company, Amgen USA Inc., Amgen Worldwide Holdings B.V., Avidia, Bergamo, BioVex, BioVex Inc., Catherex, DeCODE Genetics, Dezima Pharma, Filgrastim and Pegfilgrastim, Ilypsa, Immunex, Immunex Corporation, Immunex Rhode Island Corporation, KAI Pharmaceuticals, Kinetix Pharmaceuticals, Laboratorio Quimico Farmaceutico Bergamo, MN Pharmaceuticals, Micromet, Nuevolution, Onyx Pharmaceuticals, Onyx Pharmaceuticals Inc., Onyx Therapeutics Inc., Otezla, Synergen, and Tularik.

When was Amgen founded?

Amgen was founded in 1980.

What is Amgen's official website?

The official website for Amgen is www.amgen.com.

Where are Amgen's headquarters?

Amgen is headquartered at ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at (805) 447-1000 or via email at [email protected]


This page was last updated on 5/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.